Clinical Report: Assessment of a multi-faceted mucoadhesive buccal patch

Overview

This study evaluates the effects of a mucoadhesive buccal patch containing isotretinoin, bromelain, and limonene on inflammatory cytokine responses and tissue remodeling in oral submucous fibrosis (OSMF). Findings indicate that the formulation reduces inflammatory marker expression and collagen deposition, suggesting potential therapeutic benefits in managing OSMF.

Background

Oral submucous fibrosis (OSMF) is a chronic condition characterized by inflammation and fibrosis of the oral mucosa, often leading to restricted mouth opening and potential progression to oral squamous cell carcinoma (OSCC). Dysregulated cytokine signaling plays a critical role in the pathogenesis of OSMF, highlighting the need for targeted therapies that address these underlying mechanisms. Current treatment options are limited, underscoring the importance of innovative approaches such as localized drug delivery systems.

Data Highlights

Key Findings

• The mucoadhesive buccal patch formulation significantly reduced the expression of inflammatory cytokines IL-6, TNF-α, and MMP-2 in vitro.
• In vivo studies demonstrated improved tissue architecture and reduced collagen deposition following treatment.
• Altered expression of IL-2 and TGF-β suggests modulation of immune regulatory pathways.
• Bromelain retained enzymatic activity, promoting collagen degradation in a concentration and time-dependent manner.
• Functional improvements in mouth opening were observed in the in vivo model, indicating potential clinical benefits.

Clinical Implications

The findings suggest that the mucoadhesive buccal patch may offer a novel therapeutic strategy for managing OSMF by targeting inflammatory and fibrotic pathways. Clinicians should consider the potential of localized drug delivery systems in addressing the underlying mechanisms of oral mucosal diseases.

Conclusion

This study provides preliminary evidence supporting the use of a multi-faceted mucoadhesive buccal patch in reducing inflammation and fibrosis in OSMF. Further research is warranted to explore the mechanisms and clinical applicability of this approach.

Related Resources & Content

1. IARC, IARC, 2023 -- New study shows that one in three cases of oral cancer globally are due to smokeless tobacco and areca nut use
2. Cochrane, Cochrane, 2024 -- Interventions for the management of oral submucous fibrosis
3. ScienceDirect, ScienceDirect, 2024 -- Innovative anti-fibrotic strategy using a bromelain containing mucoadhesive patch for effective collagen breakdown and cytotoxicity in oral submucous fibrosis
4. Journal of Crohn's and Colitis — Mucosal kinase activity and inflammatory profiles in inflammatory bowel disease, and in relation to tofacitinib response
5. Archives of Toxicology — Influence of miR-24-3p and miR-146a-5p on the Maturation of Dendritic Cells Triggered by Contact Sensitizers
6. Hernia — Hydrogel-Enhanced Mesh Reduces Tissue Response Associated with Polypropylene Mesh Implants: Implications for Hernia Surgery
7. Journal of Crohn's and Colitis — Mucosal Cytokine Expression Associated With Deep Endoscopic Mucosal Healing in Ulcerative Colitis
8. New study shows that one in three cases of oral cancer globally are due to smokeless tobacco and areca nut use – IARC
9. Interventions for the management of oral submucous fibrosis | Cochrane
10. Innovative anti-fibrotic strategy using a bromelain containing mucoadhesive patch for effective collagen breakdown and cytotoxicity in oral submucous fibrosis - ScienceDirect